Aspen Says Reshaping Has Been ‘Painful’ But Is Over Now

CEO Saad Talks About Key Shift To Emerging Markets

 
• By Dean Rudge

Fresh from announcing the €642m ($762m) divestment of its Thrombosis business in Europe to Mylan, Aspen Pharmacare management walked investors through its full-year earnings, explaining in detail the company’s ambitions to focus on emerging markets.

Business decline
Aspen says it has finished its company 'reshaping' following a number of divestments • Source: Shutterstock

More from Earnings

More from Business